Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan.
PLoS One. 2021 Nov 15;16(11):e0259389. doi: 10.1371/journal.pone.0259389. eCollection 2021.
To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with poorly controlled rheumatoid arthritis (RA) treated with conventional synthetic, targeted synthetic, or biologic disease-modifying antirheumatic drugs (DMARDs), we conducted a subgroup (post hoc) analysis of Japanese patients participating in the SENSE study.
Data for Japanese patients (n/N = 118/1629) from the global, multicenter, cross-sectional, observational SENSE study were analyzed. The primary endpoint was the global satisfaction subscore assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Other patient-reported outcomes included self-reported RA medication adherence and Work Productivity and Activity Impairment-RA. Patient perspectives included patients' expectations and preference of pharmacologic treatment.
Median (range) age and RA disease duration were 67.0 (18.0-87.0) years and 8 (0.0-54) years, respectively; 81.4% of patients were female. Mean (SD) TSQM global satisfaction subscore was 56.8 (17.5), and only 5.9% of patients reported good satisfaction with treatment (TSQM global ≥80). Mean (SD) self-reported treatment adherence using VAS was high (93.5% [13.8%]). Mean (SD) total work productivity impairment was 45.6% (32.0%); presenteeism contributed toward more total work productivity impairment (43.9% [30.4%]) than absenteeism (8.3% [24.4%]). Patients expected improvement in all parameters from their treatment, especially improvement in joint symptoms. Most patients (80.7%) preferred oral medication and 18.7% preferred monotherapy. Patient acceptability of potentially manageable side effects was high (7.5%-34.0%). Although most patients (81.3%) found combination therapy acceptable, 43.2% were receiving DMARD monotherapy.
Although most Japanese patients with RA with moderate-to-high disease activity were dissatisfied with their current DMARD treatment, high treatment adherence, high acceptability of combination therapy, high acceptability of manageable potential side effects, and preference for oral medication were reported. Data support the development of a more individualized and patient-centric approach for RA treatment.
评估治疗满意度、疾病结局以及接受传统合成药物、靶向合成药物或生物 DMARDs 治疗的病情控制不佳的类风湿关节炎（RA）患者的观点，我们对 SENSE 研究中的日本患者进行了亚组（事后）分析。
分析了全球、多中心、横断面、观察性 SENSE 研究中日本患者的数据（n/N = 118/1629）。主要终点是使用治疗满意度问卷药物版（TSQM）1.4 评估的总体满意度亚评分。其他患者报告的结果包括自我报告的 RA 药物依从性和工作生产力和活动障碍-RA。患者观点包括患者对药物治疗的期望和偏好。
中位（范围）年龄和 RA 疾病持续时间分别为 67.0（18.0-87.0）岁和 8（0.0-54）年，81.4%的患者为女性。平均（标准差）TSQM 总体满意度亚评分 56.8（17.5），仅有 5.9%的患者报告治疗满意度良好（TSQM 总体≥80）。使用 VAS 评估的自我报告治疗依从性平均值较高（93.5%[13.8%]）。平均（标准差）总工作生产力受损率为 45.6%（32.0%）；与缺勤（8.3%[24.4%]）相比，出勤（43.9%[30.4%]）导致更多的总工作生产力受损。患者期望从治疗中获得所有参数的改善，尤其是关节症状的改善。大多数患者（80.7%）更喜欢口服药物，18.7%更喜欢单药治疗。患者对潜在可管理副作用的接受度较高（7.5%-34.0%）。尽管大多数患者（81.3%）认为联合治疗可接受，但仍有 43.2%的患者接受 DMARD 单药治疗。
尽管大多数病情活动度中至高度的日本 RA 患者对目前的 DMARD 治疗不满意，但仍报告了高治疗依从性、高联合治疗可接受性、高潜在可管理副作用可接受性以及对口服药物的偏好。数据支持为 RA 治疗制定更个体化和以患者为中心的方法。
